EUVIMEDEUVIMED entdecken
Open Access

Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib

Serena Muratcioglu iD, Christopher A Eide iD, Chien-Lun Hung iD, Kent Gorday iD, Emily Sumpena iD, Wenqi Zuo iD, Jay T Groves iD, Brian J Druker iD, John Kuriyan iD

Science Signaling · 2025

DOI: 10.1126/scisignal.adt5931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Signaling, 2025. Verfasst von Serena Muratcioglu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Vanderbilt University, Nashville, TN, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Proto-Oncogene Proteins c-abl, Fusion Proteins, bcr-abl, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chromosomal translocations that fuse ABL1 to BCR or TEL cause human leukemias. In BCR-ABL and TEL-ABL fusion proteins, oligomerization and loss of an autoinhibitory myristoylation site in the SH3 domain of ABL lead to increased ABL tyrosine kinase activity. We assessed the ability of asciminib, an allosteric inhibitor of BCR-ABL that binds to the myristoyl-binding site in the ABL kinase domain, to inhibit these fusion proteins. Although the ABL components of the two fusion proteins have identical sequences, asciminib was much less effective against TEL-ABL than it was against BCR-ABL in cell-growth assays. In contrast, ATP-competitive tyrosine kinase inhibitors, such as imatinib and ponatinib, were equally effective against both fusion proteins. A helix in the ABL kinase domain that closes over bound asciminib was required for the sensitivity of BCR-ABL to the drug but had no effect on that of TEL-ABL, suggesting that the native autoinhibitory mechanism that asciminib engages in BCR-ABL is disrupted in TEL-ABL. Single-molecule microscopy demonstrated that BCR-ABL was mainly dimeric in cells, whereas TEL-ABL formed higher-order oligomers, which promoted trans-autophosphorylation, including of a regulatory phosphorylation site (Tyr 89 ) in the SH3 domain of ABL. Nonphosphorylated TEL-ABL was intrinsically susceptible to inhibition by asciminib, but phosphorylation at Tyr 89 disassembled the autoinhibited conformation of ABL, thereby preventing asciminib from binding. Our results demonstrate that phosphorylation determines whether an ABL fusion protein is sensitive to allosteric inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsProto-Oncogene Proteins c-ablFusion Proteins, bcr-ablDrug Resistance, NeoplasmLymphocytesOncogene Proteins, FusionHumansPhosphorylationAllosteric RegulationNiacinamidePyrazoles

Substanzen

asciminibProtein Kinase InhibitorsProto-Oncogene Proteins c-ablFusion Proteins, bcr-ablOncogene Proteins, FusionNiacinamidePyrazoles

Autor:innen und Institutionen

  • Department of Biochemistry, Vanderbilt University, Nashville, TN, USA.
  • Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
  • Biophysics Graduate Group, University of California, Berkeley, Berkeley, CA, USA.
  • Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.
  • Department of Chemistry, University of California, Berkeley, Berkeley, CA, USA.
  • Division of Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.

ORCID-Profile: Serena Muratcioglu, Christopher A Eide, Chien-Lun Hung, Kent Gorday, Emily Sumpena, Wenqi Zuo, Jay T Groves, Brian J Druker, John Kuriyan

Förderung

  • NIAID NIH HHS

Zitieren

APA

Muratcioglu, S., Eide, C. A., Hung, C. L., Gorday, K., Sumpena, E., Zuo, W., Groves, J. T., Druker, B. J., & Kuriyan, J. (2025). Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib. Science Signaling. https://doi.org/10.1126/scisignal.adt5931

Vancouver

Muratcioglu S, Eide CA, Hung CL, Gorday K, Sumpena E, Zuo W, et al. Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib. Science Signaling. 2025. doi:10.1126/scisignal.adt5931

BibTeX
@article{Muratcioglu2025,
  author = {Muratcioglu, Serena and Eide, Christopher A and Hung, Chien-Lun and Gorday, Kent and Sumpena, Emily and Zuo, Wenqi and Groves, Jay T and Druker, Brian J and Kuriyan, John},
  title = {Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib},
  journal = {Science Signaling},
  year = {2025},
  doi = {10.1126/scisignal.adt5931}
}
Kostenlos starten →